583 related articles for article (PubMed ID: 12927382)
21. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Li Y; Pei Y; Zhang X; Gu Z; Zhou Z; Yuan W; Zhou J; Zhu J; Gao X
J Control Release; 2001 Apr; 71(2):203-11. PubMed ID: 11274752
[TBL] [Abstract][Full Text] [Related]
22. Clonazepam release from poly(DL-lactide-co-glycolide) nanoparticles prepared by dialysis method.
Nah JW; Paek YW; Jeong YI; Kim DW; Cho CS; Kim SH; Kim MY
Arch Pharm Res; 1998 Aug; 21(4):418-22. PubMed ID: 9875469
[TBL] [Abstract][Full Text] [Related]
23. Encapsulation of p-THPP into nanoparticles: cellular uptake, subcellular localization and effect of serum on photodynamic activity.
Konan YN; Chevallier J; Gurny R; Allémann E
Photochem Photobiol; 2003 Jun; 77(6):638-44. PubMed ID: 12870850
[TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of nanoparticles containing an antihypertensive agent.
Leroueil-Le Verger M; Fluckiger L; Kim YI; Hoffman M; Maincent P
Eur J Pharm Biopharm; 1998 Sep; 46(2):137-43. PubMed ID: 9795032
[TBL] [Abstract][Full Text] [Related]
25. Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy.
Dong Y; Feng SS
Int J Pharm; 2007 Sep; 342(1-2):208-14. PubMed ID: 17560058
[TBL] [Abstract][Full Text] [Related]
26. Polymer-lipid-PEG hybrid nanoparticles as photosensitizer carrier for photodynamic therapy.
Pramual S; Lirdprapamongkol K; Svasti J; Bergkvist M; Jouan-Hureaux V; Arnoux P; Frochot C; Barberi-Heyob M; Niamsiri N
J Photochem Photobiol B; 2017 Aug; 173():12-22. PubMed ID: 28554072
[TBL] [Abstract][Full Text] [Related]
27. Preparation and characterization of a composite PLGA and poly(acryloyl hydroxyethyl starch) microsphere system for protein delivery.
Woo BH; Jiang G; Jo YW; DeLuca PP
Pharm Res; 2001 Nov; 18(11):1600-6. PubMed ID: 11758769
[TBL] [Abstract][Full Text] [Related]
28. Cellular delivery of PEGylated PLGA nanoparticles.
Pamujula S; Hazari S; Bolden G; Graves RA; Chinta DD; Dash S; Kishore V; Mandal TK
J Pharm Pharmacol; 2012 Jan; 64(1):61-7. PubMed ID: 22150673
[TBL] [Abstract][Full Text] [Related]
29. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
Mehta AK; Yadav KS; Sawant KK
Curr Drug Deliv; 2007 Jul; 4(3):185-93. PubMed ID: 17627492
[TBL] [Abstract][Full Text] [Related]
30. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
Niu X; Zou W; Liu C; Zhang N; Fu C
Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638
[TBL] [Abstract][Full Text] [Related]
31. 5-Fluorouracil-loaded PLA/PLGA PEG-PPG-PEG polymeric nanoparticles: formulation, in vitro characterization and cell culture studies.
Ocal H; Arica-Yegin B; Vural I; Goracinova K; Caliş S
Drug Dev Ind Pharm; 2014 Apr; 40(4):560-7. PubMed ID: 23596973
[TBL] [Abstract][Full Text] [Related]
32. Characterization of nanoparticle uptake by endothelial cells.
Davda J; Labhasetwar V
Int J Pharm; 2002 Feb; 233(1-2):51-9. PubMed ID: 11897410
[TBL] [Abstract][Full Text] [Related]
33. Poly(D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane.
Li Z; Liu K; Sun P; Mei L; Hao T; Tian Y; Tang Z; Li L; Chen D
J Microencapsul; 2013; 30(5):432-40. PubMed ID: 23517067
[TBL] [Abstract][Full Text] [Related]
34. Different ratios of lactide and glycolide in PLGA affect the surface property and protein delivery characteristics of the PLGA microspheres with hydrophobic additives.
Chung TW; Tsai YL; Hsieh JH; Tsai WJ
J Microencapsul; 2006 Feb; 23(1):15-27. PubMed ID: 16830974
[TBL] [Abstract][Full Text] [Related]
35. In vitro degradation of poly (D, L-lactide-co-glycolide) nanoparticles loaded with linamarin.
Hussein AS; Abdullah N; Ahmadun FR
IET Nanobiotechnol; 2013 Jun; 7(2):33-41. PubMed ID: 24046903
[TBL] [Abstract][Full Text] [Related]
36. Liver-targeting Resibufogenin-loaded poly(lactic-co-glycolic acid)-D-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles for liver cancer therapy.
Chu Q; Xu H; Gao M; Guan X; Liu H; Deng S; Huo X; Liu K; Tian Y; Ma X
Int J Nanomedicine; 2016; 11():449-63. PubMed ID: 26869788
[TBL] [Abstract][Full Text] [Related]
37. Pure antiestrogen RU 58668-loaded nanospheres: morphology, cell activity and toxicity studies.
Ameller T; Marsaud V; Legrand P; Gref R; Renoir JM
Eur J Pharm Sci; 2004 Feb; 21(2-3):361-70. PubMed ID: 14757510
[TBL] [Abstract][Full Text] [Related]
38. Physicomechanical properties of biodegradable poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) films in the dry and wet states.
Kranz H; Ubrich N; Maincent P; Bodmeier R
J Pharm Sci; 2000 Dec; 89(12):1558-66. PubMed ID: 11042603
[TBL] [Abstract][Full Text] [Related]
39. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy.
Schliehe C; Schliehe C; Thiry M; Tromsdorf UI; Hentschel J; Weller H; Groettrup M
J Control Release; 2011 May; 151(3):278-85. PubMed ID: 21223984
[TBL] [Abstract][Full Text] [Related]
40. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects.
Tahara K; Yamamoto H; Hirashima N; Kawashima Y
Eur J Pharm Biopharm; 2010 Mar; 74(3):421-6. PubMed ID: 20034563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
